FDA Could Shift Assessment Of Drug-Induced Liver Injury In Clinical Trials
Agency officials, industry and academia contemplate a new approach to gauging drug-induced liver injury by using individual patients’ baseline liver enzyme measurements, a move that some say could eliminate problems with the use of the upper limit of normal and allow for the assessment of DILI in cases where there is underlying liver injury.
You may also be interested in...
Agency soliciting contractor to produce 37 drugs withdrawn because of liver injury; goal is developing better tools for evaluating compounds in the pipeline.
March event will look at best ways to detect and assess drug liver injury causation as agency mulls reopening the 2009 final guidance.
Efforts to foster innovation may have been the major theme for FDA in 2013, with new and expanded programs to expedite review of drugs for unmet medical needs dominating headlines, but senior agency officials also describe continued advances on the safety side of the regulatory equation.